Guanadrel. A new antihypertensive drug

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Therapeutics

Background:

• Hypertension remains a significant global health concern requiring effective therapeutic agents.
• Adrenergic neuron inhibitors, like guanethidine sulfate, have been used but are associated with notable side effects.
• There is a continuous need for antihypertensive medications with improved safety and efficacy profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of guanadrel sulfate as an antihypertensive agent.
• To compare the therapeutic profile of guanadrel sulfate with existing treatments, particularly guanethidine sulfate.
• To determine the suitability of guanadrel sulfate for different severity levels of hypertension.

Main Methods:

• A multicenter clinical trial involving 199 outpatients with varying degrees of hypertension.
• Administration of guanadrel sulfate to patients categorized by diastolic blood pressure.
• Systematic monitoring of antihypertensive efficacy and adverse events by 11 investigators.

Main Results:

• Guanadrel sulfate demonstrated significant antihypertensive effects across mild, moderate, and severe hypertension categories.
• The drug exhibited a rapid onset and offset of action, allowing for safe and flexible dosage adjustments.
• Adverse effects were infrequent, particularly at lower doses, with no observed organ toxicity or central nervous system effects.

Conclusions:

• Guanadrel sulfate is an effective antihypertensive medication suitable for diverse patient populations.
• Its favorable pharmacokinetic profile and safety margin suggest it as a valuable therapeutic option.
• Guanadrel sulfate is recommended as a potential Step II or Step III treatment for managing hypertension.